Proton shares (300363.SZ) announced that in order to meet the rapid growth of preclinical and early clinical (CRO) business development needs, the company plans to acquire China Gateway Pharmaceutical held by Shanghai ChemPartner. at a price of RMB 266 million in cash 100% equity of Pharmaceutical (Shanghai) Co., Ltd.
China Gateway Pharmaceutical was established in 2008 and is located in Hangzhou Bay Development Zone, Fengxian District, Shanghai. It is a wholly-owned secondary subsidiary of ChemPartner (300149.SZ), serving as a global small molecule drug R&D and production service Supplier, mainly committed to providing customers with process development and production services for intermediates and APIs required from preclinical research to various clinical trial stages.China Gateway Pharmaceutical is currently in a state of shutdown due to the renovation of factories and facilities.
After the completion of this transaction, China Gateway Pharmaceutical’s existing comprehensive laboratory, kilogram laboratory and pilot plant can provide production capacity guarantee for the company to further expand its CRO business; at the same time, China Gateway Pharmaceutical will also form with the company’s Shanghai R&D Center The linkage will help improve the switching efficiency of the company’s projects from research and development to production, and form a synergistic effect of research and production; in addition, China Gateway Pharmaceutical, as one of the earliest companies engaged in small molecule drug research and development and production services in China, has a good customer base. And the project delivery experience will help the company to further expand its domestic business, so as to gradually promote the implementation of the company’s end-to-end integrated pharmaceutical service platform strategy.
